Biopharma & Life Sciences
Alto Neuroscience Executive Compensation (FY25)
ANRO · Executive and director compensation, fiscal 2024 to 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Alto Neuroscience brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 2, 2026Latest filing (DEF 14A): March 26, 2026
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
86 figures on this page: 82 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Amit Etkin: $4,065,848 → $2,188,487 (46.2% lower)
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Amit Etkin President, Chief Executive Officer, and Chair of the Board | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Hanley Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Nicholas Smith Chief Financial Officer and Chief Business Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Amit Etkin President, Chief Executive Officer, and Chair of the Board | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Nicholas Smith Chief Financial Officer and Chief Business Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Michael Hanley Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Amit Etkin | RSU | ◇ | = | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Nicholas Smith | Option | ◇ | — | ◇ | 2/4/2035 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Hanley | Option | ◇ | — | ◇ | 2/4/2035 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Christopher Nixon Cox Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Gwill York | — | — | ◇ | — | — | — | ◇ |
Raymond Sanchez, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Andrew Dreyfus | ◇ | — | ◇ | — | — | — | ◇ |
Husseini Manji, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Po Yu (Jeff) Chen, Ph.D | ◇ | — | — | — | — | — | ◇ |
Maha Radhakrishnan, M.D | ◇ | — | — | — | — | — | ◇ |
Amit Etkin, M.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Amit Etkin (President, Chief Executive Officer, and Chair of the Board), FY2025 total compensation $2,188,487 (base salary $650,671) [exec_comp, SEC accession 0001104659-26-035180, filed 2026-03-26]What this page does not include
Everything above is a fact Alto Neuroscience disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
86 figures on this page: 82 cited to the filing that reported them, 4 calculated from figures it prints.
82 cited to the filing
4 calculated from the filing
Documents cited
- 0001104659-26-035180Non-Employee Director Compensation · Outstanding Equity Awards at Fiscal Year End · Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Alto Neuroscience executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/ANRO (accessed 2026).
Short form: data: Velarion
The Alto Neuroscience brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Alto Neuroscience and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}